Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Operating Margin (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Operating Margin for 13 consecutive years, with 6450.83% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 1071.0% to 6450.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8847.85% through Dec 2025, down 90243.0% year-over-year, with the annual reading at 11517.08% for FY2025, 841360.0% down from the prior year.
  • Operating Margin hit 6450.83% in Q4 2025 for Vistagen Therapeutics, up from 7772.48% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 96633.33% in Q1 2025 to a low of 42802.56% in Q1 2022.
  • Historically, Operating Margin has averaged 2049.0% across 5 years, with a median of 5901.1% in 2022.
  • Biggest five-year swings in Operating Margin: tumbled -4139555bps in 2022 and later soared 10355955bps in 2025.
  • Year by year, Operating Margin stood at 2943.85% in 2021, then plummeted by -84bps to 5425.83% in 2022, then surged by 65bps to 1918.25% in 2023, then tumbled by -237bps to 6461.54% in 2024, then increased by 0bps to 6450.83% in 2025.
  • Business Quant data shows Operating Margin for VTGN at 6450.83% in Q4 2025, 7772.48% in Q3 2025, and 6477.05% in Q2 2025.